Purpose Following the establishment of adjuvant carboplatin in stage I testicular seminoma
as a standard, we adopted this treatment for all stage I seminoma patients. We report our 8 …

OBJECTIVES: Adjuvant carboplatin is used as adjuvant therapy in Stage I testicular
seminoma. Although cure is the rule, relapses still occur, especially in high-risk populations …

Background The administration of carboplatin AUC 7 has become a standard adjuvant
option for patients undergoing orchiectomy for stage I seminoma, in alternative to …

Objectives. Adjuvant radiotherapy produces excellent disease-free rates in clinical Stage I
seminoma. However, concern is growing about side effects and late hazards of this …

Background The purpose of the protocol was to reduce the treatment burden in clinical stage
I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively …

Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with
clinical stage I seminoma. The aim was to reduce both the risk of relapse and the proportion …

OBJECTIVE To evaluate, in a retrospective multicentre study, the long-term oncological
efficacy and morbidity of using carboplatin as an alternative treatment for patients with …

Purpose Adjuvant carboplatin is one of three management strategies that may follow
inguinal orchiectomy in clinical stage I seminoma. However, little is known about the …

Background Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma,
though there is a paucity of long‐term safety data. Aim Our objective was to report long‐term …

Abstract Clinical stage I (CS I) seminoma has been the subject of various studies aimed at
finding the ideal treatment. Due to its high radiosensitivity, radiotherapy has been the …